Back to top
more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$22.40 USD

22.40
1,571,985

-0.14 (-0.62%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $22.25 -0.15 (-0.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Pacira (PCRX) Down 3.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Pacira (PCRX) Gets FDA Nod for Exparel in Pediatric Patients

by Zacks Equity Research

The FDA approves Pacira's (PCRX) Exparel for use in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia.

Zacks Equity Research

Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues Miss

by Zacks Equity Research

Pacira's (PCRX) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Exparel sales rise year over year.

Zacks Equity Research

Pacira (PCRX) Q4 Earnings Beat Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of 6.10% and -0.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AMRX or PCRX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AMRX vs. PCRX: Which Stock Is the Better Value Option?

Zacks Equity Research

Pacira (PCRX) Gets European Commission Approval for Exparel

by Zacks Equity Research

The EC approves Pacira's (PCRX) Exparel for treating post-operative pain in adults and as a field block for treating somatic post-operative pain from small- to medium-sized surgical wounds in adults.

Zacks Equity Research

Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Pacira's (PCRX) both bottom and the top line surpass estimates in Q3. Exparel sales rise year over year.

Zacks Equity Research

Pacira (PCRX) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of 3.03% and 1.90%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pacira (PCRX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Pacira BioSciences (PCRX) Enters Oversold Territory

by Zacks Equity Research

Pacira BioSciences (PCRX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Zacks Equity Research

Is Pacira BioSciences (PCRX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (PCRX) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Pacira (PCRX) Gains Positive CHMP Opinion for Exparel in EU

by Zacks Equity Research

The CHMP gives a positive opinion recommending an approval for Pacira's (PCRX) Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.

Zacks Equity Research

Pacira (PCRX) Up 4.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Is Pacira BioSciences (PCRX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (PCRX) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Onconova's Cancer Study Fails to Meet Endpoint, Shares Down

by Zacks Equity Research

Onconova's (ONTX) shares fall more than 60% after its phase III study on intravenous rigosertib in patients with higher-risk myelodysplastic syndromes did not meet the primary endpoint.

Zacks Equity Research

Turning Point Therapeutics (TPTX) Looks Good: Stock Adds 5.3% in Session

by Zacks Equity Research

Turning Point Therapeutics (TPTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Zacks Equity Research

Soleno (SLNO) in Focus: Stock Moves 6.3% Higher

by Zacks Equity Research

Soleno (SLNO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Zacks Equity Research

United Therapeutics Announces FDA Acceptance of Tyvaso sNDA

by Zacks Equity Research

United Therapeutics' (UTHR) INCREASE study evaluated Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Zacks Equity Research

Aquestive Therapeutics (AQST) in Focus: Stock Moves 6.4% Higher

by Zacks Equity Research

Aquestive Therapeutics (AQST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Zacks Equity Research

Avadel (AVDL) Surges: Stock Moves 7.8% Higher

by Zacks Equity Research

Avadel (AVDL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zacks Equity Research

Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2

by Zacks Equity Research

Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.

Zacks Equity Research

Is Pacira BioSciences (PCRX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (PCRX) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Axsome's (AXSM) Earnings Beat in Q2, Pipeline Progresses

by Zacks Equity Research

Axsome (AXSM) incurs a narrower loss in the second quarter of 2020. The company remains on track to submit the NDA for AXS-05 and AXS-07.

Zacks Equity Research

Xeris Pharmaceuticals (XERS) Looks Good: Stock Adds 5.1% in Session

by Zacks Equity Research

Xeris Pharmaceuticals (XERS) saw a big move last session, as its shares more than 5% on the day, amid huge volumes.

Zacks Equity Research

Radius' (RDUS) Q2 Earnings Miss Estimates, Sales Surpass

by Zacks Equity Research

Radius (RDUS) reports a wider-than-expected loss but beats sales estimates in the second quarter.